NN3201

NN3201 is a c-Kit-targeting antibody-drug conjugate (ADC) with high affinity (KD = 0.19 pM) . NN3201 is composed of 4- (3-Tosyl-2- (tosylmethyl) propanoyl) benzoic acid-glu (PEG24-Me) -val-cit-NH-benzyloxyformic acid-MMAE (HY-178219) and an anti-c-Kit human monoclonal antibody NN2101 (HY-P991293) . NN3201 rapidly internalizes and inhibits stem cell factor (SCF) -driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits no Fc-mediated effector functions antibody-dependent cell-mediated cytotoxicity (ADCC) /complement-dependent cytotoxicity (CDC) due to reduced FcγR binding. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models. NN3201 can be used in small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) and acute myeloid leukemia (AML) research[1][2].

Product Specifications

Target

Akt; Antibody-Drug Conjugates (ADCs) ; Apoptosis; Caspase; c-Kit; ERK; Microtubule/Tubulin

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

[NN3201]

References & Citations

[1]Kim C, et al. Preclinical Antitumor Efficacy of a Novel Anti-c-Kit Antibody-Drug Conjugate, NN3201, in c-Kit-Positive Tumors. Mol Cancer Ther. 2025 Sep 24:OF1-OF14.|[2]Ko H-J, et al. In vivo efficacy and preclinical safety profile of NN3201, an anti-cKIT antibody-drug conjugate, for treating SCLC and AML. Cancer Res. 2023 April 4;83 (7_Supplement) :2648.